As the pandemic hit, we mobilised a specialist team to find an approved drug that could be repurposed as a treatment for COVID-19 and uncovered baricitinib as the strongest option. Baricitinib is now approved for emergency use in the US, Japan and India after being validated in global clinical trials, where it was shown to reduce deaths by 38%.
Using our advanced drug repurposing workflows, we discovered previously unknown anti-viral properties of baricitinib, a drug owned by Eli Lilly, which was ultimately approved by the FDA for emergency use and proven to reduce mortality of hospitalised patients by 38%.
Our novel AI-derived hypothesis for baricitinib’s combined anti-viral and anti-inflammatory mechanism of action demonstrates the value of our approach and its ability to extract and infer new scientific information.
10 April 2020 / 14 September 2020
15 June 2020
Since being identified by our team in early January, baricitinib has been tested in global clinical trials and has been given emergency use authorisation to treat hospitalised patients in the US, Japan and India.